SAN

78.56

-3.52%↓

SHL.DE

40.59

+0.35%↑

ACB

3.45

-3.36%↓

SAN

78.56

-3.52%↓

SHL.DE

40.59

+0.35%↑

ACB

3.45

-3.36%↓

SAN

78.56

-3.52%↓

SHL.DE

40.59

+0.35%↑

ACB

3.45

-3.36%↓

SAN

78.56

-3.52%↓

SHL.DE

40.59

+0.35%↑

ACB

3.45

-3.36%↓

SAN

78.56

-3.52%↓

SHL.DE

40.59

+0.35%↑

ACB

3.45

-3.36%↓

Начало・Списък с акции・Genfit

Genfit

Отворен

СекторЗдравеопазване

7.065 7.05

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

6.585

Максимум

7.115

Ключови измерители
By Trading Economics
Приходи	-10M
Продажби	36M
Марж на печалбата	-28.017
Служители	188
EBITDA	955K

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+28.87% upside

Дивиденти
By Dow Jones
Следващи печалби	2.04.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	313M
Предишно отваряне	0.02
Предишно затваряне	7.065

Настроения в новините

By Acuity

42%

58%

126 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

3.566 / 4.12 Подкрепа & съпротива

Genfit Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.02.2026 г., 23:47 ч. UTC

Горещи акции

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11.02.2026 г., 22:59 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Grab Holdings to Buy U.S.-Based Stash Financial

11.02.2026 г., 23:54 ч. UTC

Печалби

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11.02.2026 г., 23:50 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

11.02.2026 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11.02.2026 г., 23:49 ч. UTC

Печалби

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11.02.2026 г., 23:45 ч. UTC

Печалби

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11.02.2026 г., 23:42 ч. UTC

Печалби

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11.02.2026 г., 23:41 ч. UTC

Печалби

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11.02.2026 г., 23:40 ч. UTC

Печалби

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11.02.2026 г., 23:35 ч. UTC

Пазарно говорене

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11.02.2026 г., 23:18 ч. UTC

Пазарно говорене

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11.02.2026 г., 23:14 ч. UTC

Пазарно говорене

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11.02.2026 г., 22:59 ч. UTC

Печалби

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11.02.2026 г., 22:59 ч. UTC

Печалби

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11.02.2026 г., 22:59 ч. UTC

Печалби

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11.02.2026 г., 22:58 ч. UTC

Печалби

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11.02.2026 г., 22:57 ч. UTC

Печалби

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11.02.2026 г., 22:54 ч. UTC

Печалби

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11.02.2026 г., 22:53 ч. UTC

Печалби

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11.02.2026 г., 22:47 ч. UTC

Печалби

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11.02.2026 г., 22:47 ч. UTC

Печалби

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11.02.2026 г., 22:23 ч. UTC

Печалби

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11.02.2026 г., 22:22 ч. UTC

Печалби

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11.02.2026 г., 22:22 ч. UTC

Печалби

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11.02.2026 г., 22:19 ч. UTC

Печалби

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11.02.2026 г., 22:18 ч. UTC

Печалби

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11.02.2026 г., 22:18 ч. UTC

Печалби

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11.02.2026 г., 22:18 ч. UTC

Печалби

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11.02.2026 г., 22:16 ч. UTC

Печалби

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Сравнение с други в отрасъла

Ценова промяна

Genfit Прогноза

Ценова цел

By TipRanks

28.87% нагоре

12-месечна прогноза

Среден 8.403 EUR 28.87%

Висок 8.4 EUR

Нисък 8.4 EUR

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Genfit през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Genfit през последните 3 месеца.

Техническа оценка

By Trading Central

3.566 / 4.12Подкрепа & съпротива

Recent bullish events outweigh bearish events.

Настроение

By Acuity

126 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.